Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.
Twelve patients with hematologic malignancies complicated by fungal infections were treated with liposomal amphotericin B (L-AmpB). Nine patients were granulocytopenic; the three additional patients with normal granulocyte counts were immunosuppressed. All patients had biopsy findings or cultural evidence of the progression of their fungal infection while being treated with conventional amphotericin B. Doses of 0.8-1.0 mg/kg of L-AmpB were administered intravenously every 24-72 hr. Three patients had a complete remission, five had a partial remission, and four showed no improvements. A total of 161 doses of L-AmpB were administered. Fever and chills occurred on seven occasions. No hematologic or blood chemistry abnormalities related to L-AmpB treatment were observed.
D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy; D005260:Female; D006660:Histoplasmosis / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000150:complications; D008081:Liposomes / Q000008:administration & dosage*; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged; D009091:Mucormycosis / Q000150:complications / Q000188:drug therapy; D009181:Mycoses / Q000150:complications / Q000188:drug therapy*; D009369:Neoplasms / Q000150:complications*; D012514:Sarcoma, Kaposi / Q000150:complications
D008081:Liposomes; D000666:Amphotericin B